JAK1 inhibitor suspension (ARQ-255)

Overview

ARQ-255 is an alternate formulation of our JAK1 cream (ARQ-252) being investigated as a treatment for alopecia areata.

Janus kinase 1 (JAK1) inhibitor suspension (ARQ-255) is modified to deliver the drug deep into the dermis and is being investigated for the treatment of alopecia areata.

Alopecia areata

Topical JAK1 inhibitor suspension (ARQ-255) in alopecia areata.

Clinical landscape

Alopecia areata is a nonscarring type of hair loss that may present in patches or a complete absence of body and scalp hair¹
There are limited approved therapies to treat alopecia areata^2,3
Because of unpredictable and spontaneous remission, optimal duration of therapy and therapeutic dosing regimens have not been well characterized^2,3

Proposed MOA

Inhibition of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway is a promising target for the treatment of alopecia areata⁴
ARQ-255 is a selective, highly potent,^* topical, small-molecule JAK1 inhibitor formulated to deliver the drug deep into the dermis that is being investigated for the treatment of alopecia areata⁵

*In vitro data. Clinical efficacy claims cannot be made.

MOA = mechanism of action

Clinical programs

Phase 1

A phase 1 clinical trial of the topical JAK1 inhibitor suspension (ARQ-255) for the treatment of alopecia areata is ongoing.

References

1. Strazzulla et al. J Am Acad Dermatol. 2018;78:1-12. 2. Wagner. J Invest Derm Symp Proc. 2015;17:67-69. 3. Fricke and Miteva. Clin Cosmet Investig Dermatol. 2015;8:397-403. 4. Triyangkulsri and Suchonwanit. Drug Des Devel Ther. 2018;12:2323-2335. 5. Data on File. Arcutis Biotherapeutics, Inc.